SCHEMBL232232

SCHEMBL232232

COC(=O)c1cc(C(=O)c2ccc(N(C)c3ccc(Cl)cc3)cc2)cc(N(C)c2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
L3MBTL1 Q9Y468 2/20 0.50
NPC1 O15118 3/20 0.43
RAB9A P51151 3/20 0.43
HPGD P15428 2/20 0.43
LTC4S Q16873 5/20 0.42
ALDH1A1 P00352 2/20 0.42
HTT P42858 1/20 0.42
NOD2 Q9HC29 1/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
MAPT P10636 2/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
ROCK2 O75116 1/20 0.41
SNCA P37840 1/20 0.41
TSHR P16473 1/20 0.41
POLB P06746 1/20 0.40
TDP1 Q9NUW8 1/20 0.40
SRD5A2 P31213 1/20 0.40
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL232400 0.95 HPGD (0.46) LMNAL3MBTL1NPC1RAB9AHPGD
SCHEMBL232108 0.88 MAPT (0.44) LMNAL3MBTL1NPC1RAB9AHPGD
SCHEMBL231253 0.88 LMNA (0.46) LMNAL3MBTL1NPC1RAB9AHPGD
SCHEMBL231986 0.87 RAB9A (0.47) LMNAL3MBTL1NPC1RAB9AALDH1A1
SCHEMBL230136 0.87 SRD5A2 (0.51) LMNAL3MBTL1NPC1RAB9AHPGD
SCHEMBL230032 0.86 MAPT (0.44) LMNAL3MBTL1NPC1RAB9AHPGD
SCHEMBL229900 0.86 TUBB4A (0.45) LMNAL3MBTL1NPC1RAB9AHPGD
SCHEMBL231849 0.85 LMNA (0.40) LMNAL3MBTL1LTC4SALDH1A1HTT
SCHEMBL230070 0.83 LTC4S (0.58) LTC4S
SCHEMBL232237 0.83 SRD5A2 (0.56) LMNAL3MBTL1NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors BIOLIPOX AB (SW) 2012-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120004228-A1 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors LTC4S, LTB4R2, LTB4R LMNA 1141/4885L3MBTL1 324/4885NPC1 2560/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.